<DOC>
	<DOCNO>NCT00006443</DOCNO>
	<brief_summary>The purpose study compare change HIV level certain immune cell among patient different stage HIV infection . This study also see combination stavudine ( d4T ) , lamivudine ( 3TC ) , indinavir ( IDV ) , nelfinavir ( NFV ) affect level . Current finding anti-HIV drug treatment lead great understand background HIV . To find best anti-HIV treatment eliminate HIV virus , cell tissue infect HIV virus examine combination anti-HIV treatment , level HIV infection low . The ERADICATE study examine idea HIV viruses eliminate stage infection time .</brief_summary>
	<brief_title>Effectiveness Anti-HIV Drugs Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages HIV Infection</brief_title>
	<detailed_description>Recent advancement antiretroviral therapy lead good understanding natural history immunopathogenesis HIV-1 infection . To calculate degree duration antiretroviral effect necessary eliminate infection , characterization residual cellular tissue HIV reservoirs follow high-level viral suppression necessary . The ERADICATE study evaluate hypothesis complete viral inhibition possible , regardless HIV disease stage , lead HIV eradication tissue time . Patients divide 1 5 group base stage HIV infection . Patients receive oral stavudine ( d4T ) , lamivudine ( 3TC ) , indinavir ( IDV ) , nelfinavir ( NFV ) twice daily 24 week . All patient undergo basic blood sample follow HIV-1 RNA level absolute T cell subset number daily 5 day ; 3 time week 3 week ; 2 time week 4 week ; every 2 week 12 week ; monthly thereafter total 3 year . In addition , follow tissue sample baseline 2 week 6 month therapy : 1 ) lymph node ; 2 ) tonsillar ; 3 ) perirectal lymphoid ; 4 ) cerebrospinal fluid ; 5 ) semen .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are infect HIV certain test indicate stage disease . Are least 18 year old . Practice birth control study . Exclusion Criteria Patients eligible study : Have receive antiHIV medication 1 week . Have serious AIDSrelated infection illness . Require medication interferes study drug . Have peripheral neuropathy , painful condition affect nervous system . Have give drug affect immune system within 2 week study entry . Have bleed disorder include hemophilia . Abuse alcohol substance . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Lymphoid Tissue</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Polymerase Chain Reaction</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Genotype</keyword>
	<keyword>Phenotype</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Macrophages</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>In Situ Hybridization</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Cell Membrane</keyword>
	<keyword>Acute Infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>